Chimeric dengue type 2 (vaccine strain PDK-53)/dengue type 1 virus as a potential candidate dengue type 1 virus vaccine

Journal of Virology

Volumn 74, Issue 7, 2000, Pages 3020-3028

  Huang, Claire Y H ^a   Butrapet, Siritorn ^a,b   Pierro, Dennis J ^a   Chang, Gwong Jen J ^a   Hunt, Ann R ^a   Bhamarapravati, Natth ^b   Gubler, Duane J ^a   Kinney, Richard M ^a  

^a NATIONAL CENTER FOR EMERGING AND ZOONOTIC INFECTIOUS DISEASES   (United States)

^b MAHIDOL UNIVERSITY   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

DENGUE VACCINE;

ARTICLE; CHIMERA; DENGUE VIRUS; NONHUMAN; PRIORITY JOURNAL; STRUCTURAL GENE; TEMPERATURE SENSITIVITY; VIRUS ATTENUATION; VIRUS GENE; VIRUS MUTATION;

ANIMALS; BASE SEQUENCE; CELL LINE; CHIMERA; DENGUE VIRUS; DNA PRIMERS; GENOME, VIRAL; MICE; MICE, INBRED ICR; NERVOUS SYSTEM; VIRAL VACCINES; VIRULENCE;

EID: 0034096441     PISSN: 0022538X     EISSN: None     Source Type: Journal    
DOI: 10.1128/JVI.74.7.3020-3028.2000     Document Type: Article

References (51)

1. Allison, S. L., K. Stiasny, K. Stadler, C. W. Mandl, and F. X. Heinz. 1999. Mapping of functional elements in the stem-anchor region of tick-borne encephalitis virus envelope protein E. J. Virol. 73:5605-5612.
2. Bancroft, W. H., R. M. Scott, W. E. Brandt, J. M. McCown, K. H. Eckels, D. E. Hayes, D. J. Gould, and P. K. Russell. 1982. Dengue-2 vaccine: infection of Aedes aegypti mosquitoes by feeding on viremic recipients. Am. J. Trop. Med. Hyg. 31:1229-1231.
3. Barrett, A. D. T., J. H. Mathews, B. R. Miller, A. R. Medlen, T. N. Ledger, and J. T. Roehrig. 1990. Identification of monoclonal antibodies that distinguish between 17D-204 and other strains of yellow fever virus. J. Gen. Virol. 71:13-18.
4. Bhamarapravati, N., and S. Yoksan. 1997. Live attenuated tetravalent vaccine, p. 367-377. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, Wallingford, United Kingdom.
5. Bhamarapravati, N., and S. Yoksan. 1989. Study of bivalent dengue vaccine in volunteers. Lancet i:1077.
6. Bhamarapravati, N., S. Yoksan, T. Chayaniyayothin, S. Angsubphakorn, and A. Bunyaratvej. 1987. Immunization with a live attenuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull. W. H. O. 65:189-195.
7. Bray, M., and C.-J. Lai. 1991. Construction of intertypic chimeric dengue viruses by substitution of structural protein genes. Proc. Natl. Acad. Sci. USA 88:10342-10346.
8. Bray, M., R. Men, and C.-J. Lai. 1996. Monkeys immunized with intertypic chimeric dengue viruses are protected against wild-type virus challenge. J. Virol. 70:4162-4166.
9. + human cytotoxic T lymphocytes. J. Virol. 63:5086-5091.
10. Butrapet, S., C. Y.-H. Huang, D. J. Pierro, N. Bhamarapravati, D. J. Gubler, and R. M. Kinney. 2000. Attenuation markers of a candidate dengue type 2 vaccine virus, strain 16681 (PDK-53), are defined by mutations in the 5′ noncoding region and nonstructural proteins 1 and 3. J. Virol. 74:3011-3019.
11. Cahour, A., A. Pletnev, M. Vazeille-Falcoz, L. Rosen, and C.-J. Lai. 1995. Growth-restricted dengue virus mutants containing deletions in the 5′ noncoding region of the RNA genome. Virology 207:68-76.
12. Chambers, T. J., C. S. Hahn, R. Galler, and C. M. Rice. 1990. Flavivirus genome organization, expression, and replication. Annu. Rev. Microbiol. 44:649-688.
13. Chambers, T. J., A. Nestorowicz, P. W. Mason, and C. M. Rice. 1999. Yellow fever/Japanese encephalitis chimeric viruses: construction and biological properties. J. Virol. 73:3095-3101.
14. Chambers, T. J., A. Nestorowicz, and C. M. Rice. 1995. Mutagenesis of the yellow fever virus NS2B/3 cleavage site: determinants of cleavage site specificity and effects on polyprotein processing and viral replication. J. Virol. 69:1600-1605.
15. Chen, B. Q., and B. J. Beaty. 1982. Japanese encephalitis vaccine (2-8 strain) and parent (SA 14 strain) virus in Culex tritaeniorhychus mosquitoes. Am. J. Trop. Med. Hyg. 31:403-407.
16. Chen, W., H. Kawano, R. Men, D. Clark, and C.-J. Lai. 1995. Construction of intertypic chimeric dengue viruses exhibiting type 3 antigenicity and neurovirulence for mice. J. Virol. 69:5186-5190.
17. Dharakul, T., I. Kuran, N. Bhamarapravati, S. Yoksan, D. W. Vaughn, C. H. Hoke, and F. A. Ennis. 1994. Dengue virus-specific memory T cell responses in human volunteers receiving a live attenuated dengue virus type 2 candidate vaccine. J. Infect. Dis. 170:27-33.
18. Fu, J., B.-H. Tan, E.-H. Yap, Y.-C. Chan, and Y.-H. Tan. 1992. Full-length cDNA sequence of dengue type 1 virus (Singapore strain S275/90). Virology 188:953-958.
19. Guirakhoo, F., Z.-X. Zhang, T. J. Chambers, S. Delagrave, J. Arrojo, A. D. T. Barrett, and T. P. Monath. 1999. Immunogenicity, genetic stability, and protective efficacy of a recombinant, chimeric yellow fever-Japanese encephalitis virus (ChimeriVax-JE) as a live, attenuated vaccine candidate against Japanese encephalitis. Virology 257:363-372.
20. Hahn, C. S., J. M. Dalrymple, J. H. Strauss, and C. M. Rice. 1987. Comparison of the virulent Asibi strain of yellow fever virus with the 17D vaccine strain derived from it. Proc. Natl. Acad. Sci. USA 84:2019-2023.
21. Halstead, S. B. 1988. Pathogenesis of dengue: challenge to molecular biology. Science 239:476-481.
22. Halstead, S. B., and P. Simasthien. 1970. Observations related to the pathogenesis of dengue hemorrhagic fever. II. Antigenic and biologic properties of dengue viruses and their association with disease response in the host. Yale J. Biol. Med. 42:276-292.
23. Jirakanjanakit, N., M. M. Khin, S. Yoksan, and N. Bhamarapravati. 1999. Dynamics of susceptibility and transmissibility of the live, attenuated, candidate vaccine dengue-1 PDK-13, dengue-3 PGK30F3, and dengue-4 PDK-48 after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 61: 672-676.
24. Khin, M. M., N. Jirakanjanakit, S. Yoksan, and N. Bhamarapravati. 1994. Infection, dissemination, transmission, and biological attributes of dengue-2 PDK53 candidate vaccine virus after oral infection in Aedes aegypti. Am. J. Trop. Med. Hyg. 51:864-869.
25. Kinney, R. M., S. Butrapet, G.-J.J. Chang, K. R. Tsuchiya, J. T. Roehrig, N. Bhamarapravati, and D. J. Gubler. 1997. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53. Virology 230:300-308.
26. Kurane, I., and F. A. Ennis. 1997. Immunopathogenesis of dengue virus infections, p. 273-290. In D. J. Gubler and G. Kuno (ed.), Dengue and dengue hemorrhagic fever. CAB International, Wallingford, United Kingdom.
27. + cytotoxic T lymphocyte clones cross-reactive for dengue virus type 2, 3, and 4. Virology 240:169-174.
28. Lai, C. J., M. Bray, R. Men, A. Cahour, W. Chen, H. Kawano, M. Tadano, K. Hiramatsu, I. Tokimatsu, A. Pletnev, S. Arakai, G. Shamcem, and M. Rinaudo. 1998. Evaluation of molecular strategies to develop a live dengue vaccine. Clin. Diagn. Virol. 10:173-179.
29. Lewis, J. A., G.-J. Chang, R. S. Lanciotti, and D. W. Trent. 1992. Direct sequencing of large flavivirus PCR products for analysis of genome variation and molecular epidemiologic investigations. J. Virol. Methods 38:11-24.
30. Liljeström, P., S. Lusa, D. Huylebroeck, and H. Garoff. 1991. In vitro mutagenesis of a full-length cDNA clone of Semliki Forest virus: the small 6,000-molecular-weight membrane protein modulates virus release. J. Virol. 65:4107-4113.
31. + cytotoxic T lymphocyte (CTL) clones. J. Immunol. 154:1281-1295.
32. + CD8 cytotoxic T-cell clones. J. Virol. 68:3283-3288.
33. Men, R., M. Bray, D. Clark, R. M. Chanock, and C.-J. Lai. 1996. Dengue type 4 virus mutants containing deletions in the 3′ noncoding region of RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in rhesus monkeys. J. Virol. 70:3930-3937.
34. Miller, B. R., B. J. Beaty, T. H. G. Aitken, K. H. Eckels, and P. K. Russell. 1982. Dengue-2 vaccine: oral infection, transmission, and lack of evidence for reversion in the mosquito, Aedes aegypti. Am. J. Trop. Med. Hyg. 31: 1232-1237.
35. Miller, B. R., and C. J. Mitchell. 1986. Passage of yellow fever virus: its effect on infection and transmission rates in Aedes aegypti. Am. J. Trop. Med. Hyg. 35:1302-1309.
36. Monath, T. P., K. Soike, I. Levenbook, Z.-X. Zhang, J. Arroyo, S. Delagrave, G. Myers, A. D. T. Barrett, R. E. Shope, M. Ratterree, T. J. Chambers, and F. Guirakhoo. 1999. Recombinant, chimeric live, attenuated vaccine (Chimeri Vax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates. Vaccine 17:1869-1882.
37. Pletnev, A. G., M. Bray, J. Hoggins, and C.-J. Lai. 1992. Construction and characterization of chimeric tick-borne encephalitis/dengue type 4 viruses. Proc. Natl. Acad. Sci. USA 89:10532-10536.
38. Pletnev, A. G., M. Bray, and C.-J. Lai. 1993. Chimeric tick-borne encephalitis and dengue type 4 viruses: effects of mutations on neurovirulence in mice. J. Virol. 67:4956-4963.
39. Puri, B., W. M. Nelson, E. A. Henchal, C. H. Hoke, K. H. Eckels, D. R. Dubois, K. R. Porter, and C. G. Hayes. 1997. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cells. J. Gen. Virol. 78:2287-2291.
40. Rey, F. A., F. X. Heinz, C. Mandl, C. Kunz, and S. C. Harrison. 1995. The envelope glycoprotein from tick-borne encephalitis virus at 2 Å resolution. Nature 375:291-298.
41. Rice, C. M., A. Grakoui, R. Galler, and T. J. Chambers. 1989. Transcription of infectious yellow fever RNA from full-length cDNA templates produced by in vitro ligation. New Biol. 1:285-296.
42. Rigau-Pérez, J. G., G. G. Clark, D. J. Gubler, P. Reiter, E. J. Sanders, and A. V. Vorndam. 1998. Dengue and dengue haemorrhagic fever. Lancet 352: 971-975.
43. + T-cell response to dengue virus. J. Virol. 70:6540-6546.
44. Sangkawibha, N., S. Rojanasuphot, S. Ahandrink, S. Viriyapongse, S. Jatanasen, V. Salitul, B. Phanthumachinda, and S. B. Halstead. 1984. Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. Am. J. Epidemiol. 120:653-669.
45. Schoepp, R. J., B. J. Beaty, and K. H. Eckels. 1991. Infection of Aedes albopictus and Aedes aegypti mosquitoes with dengue parent and progeny candidate vaccine viruses: a possible marker of human attenuation. Am. J. Trop. Med. Hyg. 45:202-210.
46. + T-cell clones specific for the dengue virus NS3 protein: flavivirus cross-reactivity and influence of infecting serotype. J. Virol. 73: 398-403.
47. Thein, S., M. M. Aung, T. N. Shwe, M. Aye, A. Zaw, K. Aye, M. Aye, and J. Aaskov. 1997. Risk factors in dengue shock syndrome. Am. J. Trop. Med. Hyg. 56:566-572.
48. Vaughn, D. W., C. H. Hoke, Jr., S. Yoksan, R. LaChances, B. L. Innis, R. M. Rice, and N. Bhamarapravati. 1996. Testing of dengue 2 live-attenuated vaccine (strain 16681 PDK 53) in 10 American volunteers. Vaccine 14:329-336.
49. Wengler, G., D. W. Bradley, M. S. Collett, F. X. Heinz, R. W. Schlesinger, and J. H. Strauss. 1995. Flaviviridae, p. 415-427. In F. A. Murphy, C. M. Fauguet, D. H. L. Bishop, S. A. Ghabrial, A. W. Jarvis, G. P. Martelli, M. A. Mayo, and M. D. Summers (ed.), Virus taxonomy. Sixth Report of the International Committee on Taxonomy of Viruses. Springer-Verlag, New York, N.Y.
50. Wengler, G., and G. Wengler. 1993. The NS3 nonstructural protein of flaviviruses contains an RNA triphosphatase activity. Virology 197:265-273.
51. Yoksan, S., N. Bhamarapravati, and S. B. Halstead. 1986. Dengue virus vaccine development: study on biological markers of uncloned dengue 1-4 viruses serially passaged in primary kidney cells, p. 35-38. In T. D. St. George. B. H. Kay. and J. Blok (ed.), Arbovirus research in Australia. Proceedings of the Fourth Symposium. CSIRO/QIMR, Brisbane, Australia.